Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03254667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Nov 30, 2020, no change to tracked fieldsv4-v8
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Study sites: 0 to 1 · Start date changed from estimate of Sep 15, 2018 to Jul 25, 2017v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 15, 2018 to Jul 25, 2017
  3. Start date: Mar 15, 2018 to Sep 15, 2018 Study title shortened, about 8 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
Trial Details
NCT Number NCT03254667
Lead Sponsor Bausch Health Americas, Inc.
Conditions Psoriasis
Enrollment 3,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov